2025 United Kingdom Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 United Kingdom Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibodies in Oncology Market in the United Kingdom are AstraZeneca, Bristol Myers Squibb, Autolus Therapeutics, and Amgen.
AstraZeneca, headquartered in Cambridge, UK, is a global leader in oncology with a broad portfolio of antibody-based cancer therapies and a market cap of approximately $54.1 billion. The company focuses heavily on immuno-oncology, targeted therapies, and combination treatments. Bristol Myers Squibb (BMS), involved through collaborations with UK biotech firms such as Amphista Therapeutics and Autolus, markets major antibody drugs including Opdivo (nivolumab), a PD-1 checkpoint inhibitor with strong sales and wide cancer indications, making it a cornerstone in UK oncology treatments. Autolus Therapeutics, based in London, specializes in CAR-T cell therapies, an advanced form of personalized antibody-driven immunotherapy targeting blood cancers with recent FDA approval of its lead product and strong partnerships with BMS and Moderna. Lastly, Amgen, a global biopharmaceutical giant, offers Mvasi, a bevacizumab biosimilar monoclonal antibody widely used in multiple cancers, supporting its significant role in the UK oncology antibody market.
These companies combine innovative antibody platforms, immuno-oncology expertise, and strategic collaborations, positioning them at the forefront of cancer antibody therapy development and commercialization in the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibodies in Oncology Market in the United Kingdom are AstraZeneca, Bristol Myers Squibb, Autolus Therapeutics, and Amgen.
AstraZeneca, headquartered in Cambridge, UK, is a global leader in oncology with a broad portfolio of antibody-based cancer therapies and a market cap of approximately $54.1 billion. The company focuses heavily on immuno-oncology, targeted therapies, and combination treatments. Bristol Myers Squibb (BMS), involved through collaborations with UK biotech firms such as Amphista Therapeutics and Autolus, markets major antibody drugs including Opdivo (nivolumab), a PD-1 checkpoint inhibitor with strong sales and wide cancer indications, making it a cornerstone in UK oncology treatments. Autolus Therapeutics, based in London, specializes in CAR-T cell therapies, an advanced form of personalized antibody-driven immunotherapy targeting blood cancers with recent FDA approval of its lead product and strong partnerships with BMS and Moderna. Lastly, Amgen, a global biopharmaceutical giant, offers Mvasi, a bevacizumab biosimilar monoclonal antibody widely used in multiple cancers, supporting its significant role in the UK oncology antibody market.
These companies combine innovative antibody platforms, immuno-oncology expertise, and strategic collaborations, positioning them at the forefront of cancer antibody therapy development and commercialization in the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
